US FDA approves isatuximab in combination with carfilzomib and dexamethasone for the treatment of multiple myeloma (MM)

Approval for use in adults with relapsed MM who have received 1-3 previous lines of therapy was based on the Phase III IKEMA study, which showed its addition to carfilzomib and dexamethasone was associated with a 45% relative reduction in risk of disease progression or death.

Source:

Biospace Inc.